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Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes 
 
Guadalupe Javier Ortiz IV, M.S. 
Advisory Professor: Guillermina Lozano, Ph.D. 
 
Cancer predisposition by the cooperation of genetic variants, such as single 
nucleotide polymorphisms (SNPs), may be of much greater significance to public health 
than previously appreciated. Functional polymorphisms are genetic variants that alter 
gene function. Meta-analyses associate many functional polymorphisms with cancer risk. 
The MDM2 SNP309G allele is a cancer-associated functional polymorphism positioned 
in the MDM2 P2 promoter that enhances transcription factor SP1 binding, resulting in 
elevated levels of MDM2 concomitant with decreased p53 tumor-suppressor activity. 
Mdm2SNP309G/G mice are more prone to spontaneous tumor formation than Mdm2SNP309T/T 
mice, providing direct evidence for the impact of this SNP on tumor development. We 
examined the impact of SNP309 on cancer risk in response to environmental factors by 
treating SNP309 mice with ionizing radiation, UVB, or Benzo(a)pyrene. The results show 
that SNP309G cooperates with ionizing radiation to exacerbate tumor development. 
Contrastingly, ultraviolet B light or Benzo(a)pyrene exposure of skin indicates that 
SNP309G allele protects against squamous cell carcinoma susceptibility. These 
contradicting differences led us to interrogate the mechanism by which Mdm2 SNP309 
regulates tumor susceptibility in a tissue-specific manner. The assessment of potential 
transcriptional regulators in ENCODE ChIP-seq database identified transcriptional 
 vi 
repressor E2F6 as a possible negative regulator of MDM2 expression. Our data show that 
E2F6 protein is expressed at higher levels in skin keratinocytes of SNP309 mice as 
compared to lymphatic tissues. Furthermore, E2F6 binds and suppresses Mdm2 
expression in cells harboring the SNP309G allele but not the SNP309T allele. Thus, the 
Mdm2 SNP309G allele exhibits tissue-specific regulation and differentially impacts 
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Chapter 1. Introduction 
The guardian of the genome 
The TP53 gene is a tumor suppressor that encodes the p53 phosphoprotein, a 
transcription factor that is paramount in maintaining genome integrity through the 
regulation of cellular pathways. Thus, p53 is known as “the guardian of the genome” [1].  
 
Discovery and characterization of the p53 protein 
The p53 protein was first identified in 1979. The first set of experiments 
conducted in hamster fibroblast cells transformed with simian virus 40 (SV40) identified 
a host protein with a molecular weight of 53-55 kDa that co-precipitated with SV40 large 
T-antigen, suggesting that viral components interact with host proteins to alter cell 
function [2-4]. Independently, other labs corroborated the co-precipitation experiments, 
but their studies also showed that sera from SV40-infected and transformed mouse cells 
harbored the 54 kDa protein, which was not detected in uninfected 3T3 cells or normal 
sera [5-7], characterizing p53 protein as a tumor antigen. 
Several groups examined the p53 oncogenic properties by cloning p53 cDNA into 
transformed and non-transformed mouse cells. Most laboratories came to the conclusion 
that p53 was an oncogene because it was able to immortalize cells or transform them 
when cells were co-transfected with Ras V12 plasmid [8-10]. However, subsequent 
experiments showed that wild-type p53 cDNA was not able to immortalize or transform 
cells with the Ras oncogene, but rather protects against oncogenes [11-13]. Moreover, the 
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sequencing of human colon tumors showed that the TP53 gene harbors mutations and 
exhibits loss of heterozygosity [14]. Finally, in vivo studies revealed that p53-deficient 
mice had a propensity for tumor development [15]. Collectively, these data were 
conclusive in characterizing p53 protein as a tumor suppressor. 
The focus then was to understand how p53 functioned as a tumor suppressor. 
Molecular studies characterized p53 as a transcription factor that regulated genes that 
play pivotal roles in cell regulation programs [16]. An example is p21/WAF1, a gene that 
plays a role in cell-cycle arrest [17]. Studies show that the p53 protein targets genes 
through sequence-specific elements harbored within the target promoter [18-21]. Thus, 
p53 is a transcription factor with potent tumor suppressor activity. 
 
p53 activation 
 In response to stress signals, p53 transactivates many genes involved in processes 
that are critical for maintaining genomic stability and cell homeostasis [16]. The p53 
protein activates these target genes by binding to specific DNA response elements (RE's) 
in the promoter as a tetrameric structure [22, 23]. These unique DNA sequences are 
characterized as two copies of the ten base motifs RRRCWWGYYY (R: purine, W: 
adenine or thymine, Y: pyrimidine) separated by 0-13 nucleotides [18]. Numerous types 
of stress factors activate the p53 pathway [24, 25]. In response to ionizing radiation, a 
source of reactive oxygen species (ROS) and DNA breaks in the genome, p53 is activated 
via phosphorylation by the kinases ATM (Ataxia Telangiectasia Mutated) and Chk2 [26].  
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Tumor suppressor function 
Many p53 target genes, including p21 and puma, have been identified and play 
vital roles to mediate p53 functions including cell cycle arrest, DNA repair, and apoptosis 
[27-30]. The decision of the cell to undergo these programs also depends on the cell type, 
the levels of stress, and the external environment, which determine the spectrum of p53 
activation [24, 25, 31]. In response to slight damage, p53 elicits programs like DNA 
repair and cell cycle arrest to allow cells to recover and revert to normal. However, in 
response to robust insult, p53 induces programs to mediate cell death, such as apoptosis 
or senescence [16]. The p53 pathway elicits other programs that are critical barriers to 
genomic instability, including but not limited to sensitizing cells to ferroptosis [32], 
autophagy [33], and altering cell metabolism to promote oxidative stress by inhibiting the 

















Figure 1. p53 is a transcription factor that exerts its tumor-suppressor functions by 
binding to sequence-specific sites in targeting genes. Under normal conditions, many 
regulators tightly regulate the p53 protein. However, in response to cellular stress, the 
p53 protein orchestrates the transactivation of many genes that activate cellular programs 




As previously stated, the p53 tumor suppressor protein is critical for maintaining 
cell homeostasis [35, 36]. Thus, its protein levels and function are tightly regulated. 
Many negative regulators of p53 have been identified such as Trim24 [37], ARF [38], 
COP1 [39], and Pirh2 [40]; however, Mdm2 and Mdm4 are the most potent p53 
inhibitors [41].  
 
Mdm2: p53 regulator  
The Mdm2 gene was first characterized due to amplification on double minute 
chromosomes in mouse NIH-3T3 fibroblast cells that provide the cells a growth 
advantage [42]. In vivo studies have concluded that Mdm2 is a potent negative regulator 
of tumor suppressor p53 protein; mouse models with homozygous Mdm2 deletions 
exhibit embryonic lethality, a phenotype that is entirely rescued by p53 deletion [43, 44]. 
Moreover, mice lacking Mdm2 in certain cell-types, including neuronal progenitors, 
cardiomyocytes, epithelial intestinal cells, and hepatocytes show embryonic lethality, yet 
these phenotypes are ultimately rescued by p53 deletion, independent of cell-type [45, 
46]. The Mdm2 protein negatively regulates p53 activity by physically binding to the N-
terminal transactivation domain (TAD) and hindering p53 transactivation potential [47, 
48]. Also, the Mdm2 RING-domain exhibits E3 ubiquitin ligase activity which 
ubiquitinates p53 and targets it for proteasomal degradation [49-51]. 
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Mdm2 transcriptional regulation 
The Mdm2 gene harbors two promoters: a p53-independent promoter (P1) and a 
p53-dependent promoter (P2), which is located in intron 1 of the Mdm2 gene [50]. 
Expression from the P1 and P2 promoters encode the same full-length protein [52, 53]. 
However, the translation potential from the P2 promoter is eight-times higher compared 
to the P1 transcript [54].  
In response to DNA damage, the p53 protein binds to p53-responsive elements 
within the P2 promoter and promotes p53-dependent Mdm2 transactivation [55-57], thus 
establishing a negative feedback loop. The importance of the Mdm2-p53 interactions in 
response to DNA damage was further established in vivo. Mice harboring mutations in 
the p53 response elements within the Mdm2 P2 promoter are viable with no apparent 
phenotypes [57]. However, when challenged with DNA damage, the mice are 
radiosensitive and exhibit a p53-dependent myeloablation and subsequent lethality [57]. 















Figure 2. p53 and Mdm2 form a feedback loop. Under cellular stress, p53 is stabilized, 
thus increasing p53 activity and resulting in upregulation of many p53 target genes that 
promote tumor suppressor activity. The p53-mediated activation of MDM2 transcription 
generates MDM2 protein that causes MDM2-mediated ubiquitination and degradation of 
p53.  
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Mdm4 is a regulator of p53   
The Mdm4 gene encodes a 490-amino acid protein that shares similarities with its 
homolog Mdm2 [58]. Mdm4 harbors a similar C-terminal RING domain, but it does not 
exhibit E3 ligase activity [58]. Biochemical studies also show that Mdm4 forms a 
complex with the p53 protein and blocks its transactivation activity [59]. Similarly to the 
in vivo Mdm2 studies, homozygous Mdm4 deletions in mice exhibit embryonic lethality, 
a phenotype that is entirely rescued by p53 deletion [60-62]. Together, these data 
conclude that Mdm4 is a potent negative regulator of p53 activity. 
 
Attenuating the p53 pathway in human cancers 
TP53 is the most highly altered gene in human cancers with more than 50% 
harboring mutations [63, 64]. Studies investigating Li-Fraumeni syndrome (LFS), a rare 
genetic disorder characterized by predisposition to tumor development, revealed that 
inherited TP53 mutations were the cause of this familial syndrome [65]. Furthermore, 
mouse studies harboring p53 mutations also exhibit cancer phenotypes [15, 66]. The p53 
pathway can be dampened by additional mechanisms, including amplification or 
overexpression of genes encoding p53 negative regulators [48, 67, 68]. The MDM2 gene 
is amplified and overexpressed in many tumors. Early human studies described MDM2 
gene amplifications in sarcomas [48], but later studies show other tumor types, including 
glioblastomas, and breast cancer [69]. Another mechanism by which MDM2 is altered in 
cancers is through overexpression, where it correlates with tumor grade and poor 
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prognosis in mesothelioma patients [70]. Moreover, tumor studies show a mutually 
exclusive relationship between MDM2 and p53; tumors harboring MDM2 amplification 
seldom carry TP53 mutations [71, 72], thus suggesting that either alteration dampens p53 
activity. 
Studies also show that subtle alterations in the p53 pathway can be detrimental to 
overall survival. A p53 restoration study revealed that mice harboring different levels of 
p53 activity correlated with overall survival [73]. Expression of as little as 7% difference 
in p53 expression altered survival [73], thus emphasizing the importance of p53 tumor 
suppressor activity and gene-dosage effects. 
 
Haploinsufficiency of Mdm2 and Mdm4 in tumor development 
In addition, minor changes in Mdm2 and Mdm4 levels also impact survival and 
cancer risk. Mice harboring a hypomorphic Mdm2 allele that expressed ~30% of Mdm2 
protein exhibited elevated levels of p53 activity [74]. These mice were small, 
radiosensitive, and showed a reduced number of lymphocytes. This phenotype was 
rescued by p53 deletion. Moreover, these mice are resistant to the development of 
colorectal cancers in a p53-dependent manner [74]. 
Genetic studies show that Mdm2 haploinsufficiency promotes p53 activity [74-
76]. Studies examined if the loss of a single Mdm2 or Mdm4 allele would affect tumor 
development. Mouse models overexpressing Eµ-myc are susceptible to B cell 
lymphomas, and often these tumors exhibit Mdm2 overexpression but no gene 
 11 
amplification [77]. Thus, Mdm2+/+ or Mdm2+/– mice were crossed with Eµ-myc transgenic 
mice and show that Mdm2 haploinsufficiency delays B-cell lymphomagenesis compared 
to Eµ-myc transgenic harboring wild-type Mdm2 gene [75]. Another study investigated if 
reduced levels of Mdm2 or Mdm4 affected p53 response to DNA damage [76]. Mdm2+/- 
and Mdm4+/- mice are viable and exhibit a normal phenotype. However these animals 
were radiosensitive, exhibiting reduced levels of lymphocytes in the blood, and 
ultimately dying in response to a sub lethal dose of ionizing radiation [76]. Furthermore, 
double heterozygous Mdm2+/- mice Mdm4+/- mice show defects in hematopoiesis and 
brain development and are not viable, a phenotype that is rescued by deleting a single p53 
allele [76]. Collectively, these data highlight the delicate balance within the p53 pathway 
and suggest that the balance could be tissue-dependent. 
 
Single nucleotide polymorphisms (SNPs) 
Single nucleotide polymorphisms are characterized as nucleotide variants at a 
particular location of the genome, and these nucleotide differences are present in at least 
1% of a population [78]. SNPs are the most common genetic variants in the human 
genome with a frequency of approximately one in 300 bases, suggesting that there are 
close to 10 million SNPs in the genome [79, 80]. Due to their high frequency, SNPs are 
used as biological reference points in the genome, and this information can be used to 
measure evolutionary changes in genes of interest [79]. Furthermore, SNPs are relevant 
in studying human health.   
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SNPs and disease 
There is a wealth of evidence associating single nucleotide polymorphisms 
(SNPs) and disease susceptibility [81-83]. Meta-analysis studies evaluate associations 
between inherited deleterious alleles and disease risk [84, 85]. A recurrent issue in the 
meta-analysis is the consistency in associating SNPs and disease risk within study 
groups, where studies often report contradicting findings [86, 87]. One obvious reason is 
that most SNPs used in association studies are not well characterized, so their function 
and detailed mechanisms behind disease risk are poorly understood. Therefore, it is 
important to understand the functional role of SNPs to analyze better and associate its 
role in disease risk. 
 
Functional SNPs  
Most SNPs are located in noncoding sequences or in non-regulatory regions of the 
DNA, which limits their potential to disrupt gene function or cause deleterious effects on 
health or development; these SNPs are called synonymous substitutions or silent 
substitutions [88]. Functional SNPs are non-synonymous substitutions that are positioned 
within regulatory or protein coding sequences and can alter gene expression or protein 
structure, thus altering function and contributing to disease risk [89-94]. 
Functional SNPs located within promoters or enhancers alter gene expression. An 
example is FLT1-T, a SNP located in the promoter region of flt-1 within a p53-
responsive element site [89]. Flt-1 is a target of VEGF and associated with tumor 
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progression. Studies show that in response to induced DNA damage, p53 protein binds to 
the FLT1-T but not the FLT1-C promoter [89]. Thus, the FLT1-T SNP directly affects 
p53-mediated transcription in the flt-1 gene.  
Another example is MYC-335, an enhancer located upstream of the MYC gene 
that harbors SNP rs6983267, and associates with cancer risk, including colorectal cancer 
[94]. The “G” allele creates a stronger binding site for transcription factor TCF4 
compared to the “T” allele, thus increasing expression of the MYC oncogene [95]. In vivo 
studies showed that mice lacking this enhancer exhibit a modest decrease in MYC mRNA 
in intestinal crypts and are resistant to intestinal tumors, suggesting that SNP rs6983267 
plays a direct role in tumor risk [94].  
Finally, functional polymorphisms can alter gene regulation by modulating 
alternative splicing. Reduced expression levels of Lysyl oxidase-like 1 (LOX1) are 
associated with risk for pseudoexfoliation (PEX) syndrome [96]. A functional 
polymorphism (rs11638944) located downstream of the canonical LOXL1 promoter 
(intron 2) reduces the expression levels of LOXL1, mediated by modulating alternative 
splicing of LOXL1 and concomitantly reduced levels of LOXL1 mRNA in cells and 
tissues of risk allele carriers [96]. Experiments concluded that alternative splicing of 
LOXL1 pre-mRNA coupled with nonsense-mediated decay is significantly influenced by 
this SNP, which is near the splice site [96]. Thus, functional SNPs can affect gene 







Figure 3. Functional SNP alters gene regulation through multiple mechanisms. The 
SNPs are naturally occurring genetic variation in the genome. SNPs occurring in 
regulatory elements alter gene function and may cause disease.  
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SNPs in the p53 pathway 
The p53 pathway regulates many cellular programs that limit tumorigenesis 
potential in vertebrates [97, 98]; thus, the attenuation of this pathway increases tumor risk 
and creates a poor outcome [99]. Several studies show that functional polymorphisms 
harbored within genes involved in the p53 pathway, including TP53 and MDM2, alter 
gene function and affect the p53 tumor suppressor activity and modulate tumor risk in 
humans [100, 101]. Most mechanisms involving SNPs in the p53 pathway have not been 
fully elucidated. Insight into these functional mechanisms could render crucial 
information that could improve therapeutic targets and human health. 
 
TP53 codon 72   
One of the most studied SNPs in the p53 pathway is SNP rs1042522 (also known 
as p53 codon 72); It is located within the polyproline region in the TP53 gene [102]. The 
alleles (C/G) at this locus encode either a proline or arginine residue [103]. Meta-analyses 
associate P72 with cancer risk [104, 105]. Studies show that SNP rs1042522 affects the 
p53 activity discretely. In vivo studies show that mice harboring P72 exhibit increased 
growth arrest when challenged with DNA damage due to enhanced p53 binding to the 
p21 gene [106]. Contrastingly, mice harboring R72 exhibit increased apoptotic response 
when tested with DNA damage [106]. Furthermore, R72 structural conformation in p53 
enhances the transactivation of pro-apoptotic genes [106]. Together, these data show that 
functional SNPs alter gene activity. 
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  MDM2 SNP309 discovery and characterization 
The MDM2SNP309 polymorphism was identified in an investigation that 
characterized genetic variants in the MDM2 P2 promoter region. The study utilized 
genomic DNA from 50 healthy individuals and analyzed the P2 promoter and found that 
at position 309 there is a nucleotide substitution from T to G [107]. To examine the 
functional consequences of this SNP, bioinformatics and molecular biology analyses 
demonstrated that the SNP309G allele created a preferred binding site for transcription 
factor SP1. Moreover, an analysis in cell lines that harbored homozygous SNP309G 
alleles exhibited higher MDM2 expression levels compared to homozygous SNP309T 
cells, concomitantly attenuating p53 activity [107]. Thus, MDM2 SNP309G is functional 
polymorphism that alters the p53 pathway. 
 
MDM2 SNP309 is associated with cancer risk 
MDM2 SNP309G is a functional polymorphism in the p53 pathway that 
associates with increased cancer risk in many cancer types, including lung, colon, 
pancreas, endometrium, and head and neck [107-111]. The first association of the 
MDM2SNP309 polymorphism with increased tumor risk was in Li-Fraumeni syndrome 
(LFS) patients. The authors hypothesized that because SNP309G dampen p53 tumor 
suppressor activity, LFS patients harboring the SNP309G allele would be more prone to 
tumor risk compared to SNP309T individuals. The data show that the SNP309G allele 
was associated with a 10-year earlier onset of breast tumors compared to the SNP309T 
allele in LFS patients [107]. Moreover, LFS patients harboring homozygous SNP309G 
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alleles exhibited more tumors compared to SNP309T individuals [107]. Thus, the “G” 
allele may exacerbate tumor susceptibility in LFS patients by increasing MDM2 levels to 
further attenuate p53 tumor suppressor activities.  
 
MDM2 SNP309 and association studies 
Although the SNP309G allele is highly associated with increased cancer risk, 
some published studies are inconclusive [108, 112]. For example, several reports show a 
strong association of SNP309G allele with lung cancer risk in the Chinese population 
[113, 114]; however, studies conducted with American-born subjects show no association 
between SNP309G allele and lung cancer risk [115]. These contradicting data suggest 
that other factors, including race, may impact SNP309G-dependent cancer risk. Race is 
exemplified in a study that showed that genetic variant SNP285C, a SNP harbored within 
the MDM2 P2 promoter and only expressed in Caucasians, antagonizes the SNP309G 
allele cancer risk and protects against breast, ovarian, and endometrial cancers [116, 117]. 
However, the SNP285C allele did not antagonize the effect of the SNP309G allele on 
prostate cancer risk [116], suggesting that the SNP285C allele may be factor-dependent. 
Meta-analyses suggest that gender impacts SNP309G-dependent cancer risk. For 
example, a study associating SNP309G with lung cancer risk indicate that homozygous G 
alleles raised lung cancer risk among females [112]. A second study associating 
SNP309G with osteosarcoma showed that female osteosarcoma patients exhibited 
significantly increased risk (GG versus TT; odds ratio, 4.26; 95% CI, 1.61-11.25) [118]. 
These studies show the association of MDM2 SNP309G with cancer risk in females 
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MDM2 SNP309 mechanism 
Mechanistically the SNP309G sequence creates a stronger binding site for the 
transcription factor SP1 in the MDM2 P2 promoter [107]. SP1 is a zinc finger that binds 
to GC-rich regions and is a potent transcriptional activator [116]. In vitro studies 
measured the binding affinity of SP1 to DNA fragments containing either the SNP309G 
or the SNP309T allele. The data concluded that the affinity was modestly higher in the 
SNP309G allele (~22%) compared to the SNP309T allele [117]. However, this difference 
is enough to significantly increase MDM2 mRNA expression levels in cells harboring the 
SNP309G compared to the SNP309T allele and concomitantly decrease p53 activity 
[107].  
To investigate the direct impact of SNP309G on tumor risk, genetically 
engineered mice harboring the Mdm2 SNP309 alleles were generated and evaluated for 
tumor susceptibility. A comparison of human and mouse promoter sequences showed 
weak conservation (82%) and absence of the Mdm2 SNP309 [119]. Therefore, 
Mdm2SNP309G/G and Mdm2SNP309T/T mice were generated by replacing the mouse intron 1 
(containing the entire P2 promoter) with the corresponding human intron 1 with either the 
G or T polymorphism [119]. These models facilitate an analysis of the direct impact of 
Mdm2 P2 promoter SNP309 on transcriptional regulation.  
First, the authors evaluated the effect of the SNP309G allele on Mdm2 expression 
and p53 tumor suppressor activity. Lymphatic tissues, including thymi and spleen, 
harvested from Mdm2SNP309G/G mice show significantly higher Mdm2 expression levels 
compared to Mdm2SNP309T/T tissues [119]. Consistently, brain and uteri from 
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Mdm2SNP309G/G mice also show relatively higher Mdm2 expression compared to 
Mdm2SNP309T/T tissues, but those data were not statistically significant. The authors also 
examined the effects of SP1 on Mdm2 expression in SNP309 tissues. The data show that 
spleens from Mdm2SNP309G/G mice exhibited decreased Mdm2 expression levels after 
treatment with Mithramycin A, a known SP1 inhibitor, but there was no effect on Mdm2 
expression in spleens from Mdm2SNP309T/T mice [119]. To analyze the effects of Mdm2 
SNP309G on p53 activity, spleen tissues from SNP309 mice were treated with 1Gy of 
ionizing radiation (IR) and evaluated for apoptotic response 3-hours post IR. The data 
show that spleens from Mdm2SNP309G/G mice exhibited decreased apoptotic response 
compared to Mdm2SNP309T/T mice [119]. Thus the p53 pathway is attenuated in tissues 
from Mdm2SNP309G/G mice. Finally, Mdm2SNP309G/G mice are more susceptible to 
spontaneous tumor formation and exhibit a significantly lower overall survival compared 
to Mdm2SNP309T/T mice [119]. These data confirm that the SNP309G allele is the “at risk” 
allele in tumor studies.  
 
Evidence that SNP309G may exhibit a protective role in cancer 
Recent studies have identified a protective role of SNP309G in some cancers 
[108]. For example, multiple studies that included Asian and Caucasian cohorts associate 
the SNP309G allele with a decreased risk and late onset of prostate cancer compared to 
patients harboring the SNP309T allele [108, 120]. In these studies, the authors discussed 
the possibility that hormones may influence the SNP309G allele effects on prostate tumor 
risk. However, this question has not been experimentally tested [120]. There is some 
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evidence to support that gender influences SNP309G dependent tumor risk. One study 
shows that female melanoma patients harboring homozygous SNP309G alleles exhibited 
a later onset compared to those harboring homozygous SNP309T alleles [121].  
A recent study evaluated the influence of the MDM2SNP309 polymorphism in 
survival outcome of surgically resected Non-small-cell lung carcinoma (NSCLC). 
Reports show no association between SNP309G and lung adenocarcinoma in a Japanese 
population. However, when lung adenocarcinoma was stratified by pathological stage 1 
disease, patients harboring homozygous SNP309T alleles exhibited significantly shorter 
survivals compared to patients harboring homozygous SNP309G or heterozygous 
SNP309T/G alleles. Thus the homozygous SNP309T allele is a prognostic marker for 
poorer survival in stage 1 adenocarcinoma in a Japanese cohort. Finally, A recent study 
demonstrated a decreased risk of developing oral squamous cell carcinoma (OSCC) for 
the MDM2 SNP309G group [122] with pronounced susceptibility in the MDM2 SNP309T 
group, suggesting MDM2 SNP309G may be protective in a cell-dependent manner. 
Collectively, these data suggest that MDM2 SNP309 appears to differentially impact 
tumor susceptibility in different cancers for reasons that are currently unknown.  
 
Gene-environment interactions and disease risk 
 Gene-environment studies focus on understanding and measuring the influence of 
environmental exposure on disease risk in different cohorts [123]. Genetics and 
environment contribute to disease risk, but limited studies have examined how these 
factors interact to promote disease risk. Furthermore, meta-analysis studies that focus on 
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genetic epidemiology are seldom contradicting [124, 125]. Thus mechanisms examining 
gene-environment interactions are paramount to precisely delineating their influence in 
disease causation within a cohort.   
 
SNP-environmental interactions and cancer risk  
Genome-wide association studies (GWAS) have been crucial in identifying many 
genetic variants associated with cancer risk [126, 127]. The addition of environmental 
exposure to GWAS studies may provide further insight into SNP-dependent cancer risk 
or other susceptibilities otherwise concealed by heterogeneity in subgroups [128]. Here 
are several examples. 
One study examined the influence of different environmental exposures, including 
diet, UV, smoking, and alcohol consumption with a panel of SNPs associated with 
colorectal cancer (CRC) risk in the Malaysian population [129]. The study concluded that 
out of the 12 SNPs associated with CRC, individuals harboring the "A" allele in SNP 
rs2069521 were more susceptible to colorectal cancer risk when consuming red meat 
compared to people on a vegetarian diet [129]. Another study examined the influence of 
smoking on several SNPs associated with lung cancer [130]. The data show that 
particular SNPs increase lung cancer risk as well as promote chronic obstructive 
pulmonary disease, an established risk factor for lung cancer [130]. Finally, a study 
examined the influence of ultraviolet radiation in SNPs associated with non-melanoma 
skin cancer (NMSC) risk [131]. Studies suggest that the NMSC etiology may be through 
an immunosuppression pathway; thus, SNPs in cytokines and signaling molecules 
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correlated with UV-induced immunosuppression pathway were evaluated [131]. The 
results show that a genetic variant of IL10 increased the risk of basal cell carcinoma and 
squamous cell carcinoma [131]. These data show correlations between environmental 
exposures to SNPs associated with cancer risk, yet these data do not reveal the 
mechanisms. There is a need to mechanistically understand how environmental factors 
interact with functional polymorphisms to modulate cancer risk. 
 
Hypotheses and Rational 
Studies show that Mdm2SNP309G/G mice are more prone to tumor development than 
Mdm2SNP309T/T mice, providing direct data for the impact of the SNP309G allele on 
spontaneous tumor development [119]. Moreover, p53 mutant mice harboring the 
SNP309G allele are more prone to tumors compared to p53 mutant mice with the 
SNP309T allele, suggesting that the SNP309G influences p53 mutant mice and promotes 
cancer risk similar to studies in LFS patients [119]. To better characterize the gene-
environment interactions of SNP309G in cancer risk, I propose to challenge SNP309 
mice with various environmental factors to examine the influence of SNP309 in 
spontaneous tumor development. Ergo, I hypothesize that Mdm2 SNP309G cooperates 
with environmental factors to promote spontaneous tumor development. The goal of my 
study is to characterize environment-SNP309G interactions and to elucidate the 
mechanism(s) involved in SNP309G-dependent tumor development. Thus, I challenged 





















Chapter 2. Results 
Previous studies determined that Mdm2SNP309G/G mice are more prone to 
spontaneous tumor formation than Mdm2SNP309T/T mice [119], providing direct evidence 
for the impact of this SNP in tumor development. To further characterize the cancer risk 
potential of the SNP309G allele, I treated Mdm2SNP309T/T and Mdm2SNP309G/G mice in a 
C57BL/6 background with low-dose ionizing radiation to study the effects of 
environmental factors on a tumor phenotype in this model; hence, I hypothesized that 
low-dose ionizing radiation exacerbates tumor development in Mdm2SNP309G/G mice 
compared to Mdm2SNP309T/T mice.  
 Ionizing radiation generates DNA double strand breaks and reactive oxygen 
species (ROS), direct mediators of p53 activation [132]; furthermore, humans are 
consistently exposed to low-dose ionizing radiation via cosmic rays and medical imaging 
procedures [133]. The C57BL/6 strain is appropriate for this experiment due to the 
extensive use of this strain in ionizing radiation tumor studies [134]. A single dose of 
1Gy ionizing radiation was experimentally determined to be representative of low-dose 
ionizing radiation because it is the minimal dose that cannot induce tumors in a wild-type 
C57BL/6 strain background [134]. To this end, I generated cohorts of Mdm2SNP309T/T and 
Mdm2SNP309G/G mice in a C57BL/6 background, treated them with 1Gy ionizing radiation, 
and followed them for tumor formation. 
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Low-dose ionizing radiation preferably attenuates p53 activity in tissues from 
Mdm2SNP309G/G mice compared to Mdm2SNP309T/T mice  
I first characterized the effect of low-dose IR on Mdm2 levels and p53 activity in 
spleens of Mdm2SNP309T/T and Mdm2SNP309G/G mice in a C57BL/6 background. I evaluated 
the Mdm2 expression in spleens from irradiated Mdm2SNP309T/T Mdm2SNP309G/G mice 3 
hours post IR treatment. The spleens of Mdm2SNP309G/G mice showed a 7.8-fold increase 
in Mdm2 levels (p<0.0001) compared to Mdm2SNP309T/T spleens (Figure 4). Previous 
studies show that spleens of non-irradiated Mdm2SNP309T/T mice in a C57BL/6 background 
also exhibit lower Mdm2 expression compared to Mdm2SNP309G/G mice [119]. As 
expected, non-irradiated spleen samples from Mdm2SNP309G/G mice showed significantly 
higher Mdm2 basal levels (p= 0.005) as compared to spleens from Mdm2SNP309T/T mice 
(Figure 4). Next, I tested the effects of low-dose IR on p53 activity in spleens from 
Mdm2SNP309T/T Mdm2SNP309G/G mice by examining the expression levels of p53 targets, 
p21 and Puma, 3 hours post IR treatment. Consistently, the spleens of Mdm2SNP309G/G 
mice showed a significant attenuated p53 response compared to Mdm2SNP309T/T spleens 
after IR treatment (Figure 5), suggesting that low-dose IR has a stronger effect on spleens 
of Mdm2SNP309G/G mice compared to Mdm2SNP309T/T spleens by elevating Mdm2 levels 
with concomitant attenuation of the p53 response. 
To determine the effects of low-dose IR on cell survival, I examined the onset of 
apoptosis in lymphatic tissues of Mdm2SNP309G/G mice and Mdm2SNP309T/T mice post-IR. 
Mdm2SNP309G/G mouse lymphatic tissues exhibit a delay in activation of apoptosis 
compared to Mdm2SNP309T/T after low-dose IR as measured by the number of cells staining 
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positively for cleaved caspase-3 (Figure 6). At 6 hours post IR, spleen, and thymi from 
Mdm2SNP309T/T mice showed the presence of apoptotic cells compared to none in the same 
tissues of Mdm2SNP309G/G mice indicating a delayed response to IR; however, by 12 hours 
post IR, spleens, and thymi from Mdm2SNP309G/G mice showed increased apoptosis 









Figure 4. Mdm2 expression in spleen tissues of Mdm2SNP309 mice 3h post IR. RT-
qPCR analysis of Mdm2 expression in the spleens of two-day old Mdm2SNP309T/T (T/T) 
and Mdm2SNP309G/G (G/G) mice. Five mice per genotype were analyzed. The average 
expression of untreated (T/T) spleens was normalized to 1 for comparison. RplpO 
expression (housekeeping gene) was used as internal control. IR, ionizing radiation; 










Figure 5. Expression analysis of p53 targets in spleen tissues of Mdm2SNP309 mice 3h 
post IR. RT-qPCR expression analysis of p21 and puma in spleens of two-day old 
Mdm2SNP309T/T and Mdm2SNP309G/G mice 3 hours post IR treatment (1Gy). Five mice per 
genotype were analyzed. The average expression of untreated (T/T) spleens was 
normalized to 1 for comparison. RplpO expression (housekeeping gene) was used as 







Figure 6. Immunohistochemistry of spleens and thymi of Mdm2SNP309T/T and 
Mdm2SNP309G/G mice with caspase-3 antibody. The number of positive cells per field of 
view was counted in three sections per mouse. Graphs represent mean value, n = 3, mean 
±SD. Statistical significance was determined by two-way analysis of variance (ANOVA). 
IR, ionizing radiation; Mdm2SNP309T/T, T/T; Mdm2SNP309G/G, G/G. 
 
 30 
Low-dose ionizing radiation exacerbates tumor development in Mdm2SNP309G/G mice 
compared to Mdm2SNP309T/T mice 
To examine the long-term effects of low-dose IR on tumor development, I 
generated a cohort of irradiated Mdm2SNP309T/T and Mdm2SNP309G/G mice in a C57BL/6 
background and monitored for tumor development. I also observed non-irradiated 
Mdm2SNP309G/G and Mdm2SNP309T/T mice as controls. The cohort was followed for 850 days 
(121 weeks). I first analyzed tumor-free survival between non-irradiated and irradiated 
mice. Tumor-free survival shows that irradiated mice developed significantly more 
tumors (p<0.0001) than non-irradiated mice independent of genotype (Figure 7). 
Consistent with previous studies, non-irradiated Mdm2SNP309G/G mice are significantly 
more prone to tumor development (p< 0.0001) than non-irradiated Mdm2SNP309T/T mice in 
a C57BL/6 background (Figure 8). Next, I analyzed tumor-free survival between 
irradiated Mdm2SNP309G/G and Mdm2SNP309T/T mice and the data show that tumors 
developed significantly more quickly in irradiated Mdm2SNP309G/G mice than in irradiated 
Mdm2SNP309T/T mice (p<0.0001) (Figure 9). Mdm2SNP309G/G mice exhibited a median 
survival of 74 weeks. In contrast, the majority of Mdm2SNP309T/T mice survived without 
tumor development, and thus the median survival could not be calculated. 
I analyzed the tumor spectrum in non-irradiated SNP309 mice (Table 1). The data 
show that Mdm2SNP309G/G have more tumor types compared to Mdm2SNP309T/T mice. The 
tumor types from this study were similar to those previously reported [119]. I then 
analyzed the tumor incidence in irradiated Mdm2SNP309G/G and Mdm2SNP309T/T mice. The 
tumor incidence was significantly higher (p<0.0001) in Mdm2SNP309G/G mice compared to 
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Mdm2SNP309T/T mice (Figure 10). Furthermore, Mdm2SNP309G/G mice had a proclivity to 
develop lymphomas and sarcomas. However, a number of mice also developed other 
tumors, including mammary carcinomas, glioblastomas, and histiocytic sarcomas (Table 
2). Also, Mdm2SNP309G/G mice treated with 1Gy IR had significantly increased (p<0.0001) 
tumor multiplicity compared to non-irradiated genotypes and irradiated Mdm2SNP309T/T 
mice  (Figure 11). Only irradiated Mdm2SNP309G/G mice had three or more tumors per 
mouse. These data show low-dose ionizing radiation exacerbates tumor development in 










Figure 7. Tumor-free survival curves of Mdm2SNP309 mice comparing non-irradiated 
and irradiated mice. Numbers reflect mouse numbers in the cohorts. The parentheses 
represent the environmental exposure. The only group that reached median tumor-free 
survival is the G/G IR with 74 weeks. The statistical differences in the curves were 
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Figure 8. Tumor-free survival of non-irradiated Mdm2SNP309 mice. Numbers reflect 
mouse numbers in the cohorts and the parentheses represent the environmental exposure. 
No group reached median tumor-free survival. The statistical differences in the curves 










Figure 9. Tumor-free survival of gamma-irradiated Mdm2SNP309 mice. Numbers 
reflect mouse numbers in the cohorts. The parentheses represent the environmental 
exposure. The G/G IR group reached median tumor-free survival with 74 weeks. The 
statistical differences in the curves were measured using a Log-rank test. IR, ionizing 















Table 1. Tumor spectrum in non-irradiated Mdm2SNP309 mice. n represents number of 
mice that presented with tumors. The numbers in parentheses represent percent of mice 








Lymphoma  2 
Osteosarcoma  9 
Hepatocellular 1 1 
Histiocytic Sarcoma  1 










Figure 10. Tumor incidence in gamma-irradiated Mdm2SNP309 mice. The pie charts 
represent the comparison between tumor spectrum of T/T and G/G groups treated with 
gamma radiation. The comparisons were calculated using Fishers test. IR, ionizing 





















Table 2. Tumor spectrum of Mdm2SNP309 C57BL/6 mice after 1Gy IR. n represents 
number of mice that presented with tumors. The numbers in parentheses represent 







Lymphoma 4 17 
NOS  2 
Rhabdomyosarcoma  1 
Hemangiosarcoma  3 
Osteosarcoma 2 25 
Medulloblastoma  1 
Glioblastoma  1 
Neuroblastoma  1 
Adenoma 2 3 
Alveolar carcinoma  2 
Hepatocellular carcinoma 3 4 
Mammary carcinoma  2 
Renal tubule  1 
Squamous cell carcinoma  1 
Histiocytic sarcoma 1 4 
Germ cell tumor 1 2 







Figure 11. Tumor multiplicity of Mdm2SNP309 C57BL/6 mice cohort. The y-axis 
represents the number of mice with tumors. The x-axis represents number of tumors. The 






Low-dose ionizing radiation exacerbates lymphoma development in Mdm2SNP309G/G 
mice compared to Mdm2SNP309T/T mice 
I further characterized the lymphoma phenotype due to its high penetrance 
(Figure 12) where lymphoma-free survival shows irradiated Mdm2SNP309G/G mice 
developed lymphomas significantly faster (p<0.0001) compared to Mdm2SNP309T/T mice. 
To determine the lymphoma phenotype, I performed immunohistochemistry (IHC) with 
CD3 (T cell marker) and B220 antibodies (B-cell marker) and observed that lymphomas 
from Mdm2SNP309G/G mice were either T-cell or B-cell lymphomas (Figure 13), with the 









Figure 12. Lymphoma-free survival of gamma-irradiated Mdm2SNP309 mice. Numbers 
reflect mouse numbers in the cohorts. The parentheses represent the environmental 
exposure. The median lymphoma-free survival of G/G IR group was 80 weeks. The 
statistical differences in the curves were measured using a Log-rank test. IR, ionizing 











Figure 13. Lymphomas in Mdm2SNP309G/G mice exhibit either T-cell or B-cell cell-
type. The tissues were necropsied from Mdm2SNP309G/G mice. Dr. Adel El-Naggar 
identified the samples as lymphomas. The numbers in parentheses represent the 







These experiments demonstrate that the Mdm2SNP309G allele impacts p53 
activity. Experiments show that lymphatic tissues harvested from Mdm2SNP309G/G mice 
express higher Mdm2 levels and exhibit less apoptotic activity compared to 
Mdm2SNP309T/T tissues. Furthermore, Mdm2SNP309G/G mice show exacerbated spontaneous 
tumor development after low-dose IR compared to the Mdm2SNP309T/T mice. Finally, 
Mdm2SNP309G/G mice are more prone to lymphomas of either T-cell or B-cell cell-type 
origin compared to the Mdm2SNP309T/T mice. 
The effects of low-dose IR in lymphatic tissues show a delay in apoptosis in 
spleen and thymi of Mdm2SNP309G/G mice compared to Mdm2SNP309T/T tissues. Previous 
studies show that delayed apoptotic response to gamma irradiation correlated with 











Investigating the influence of Ultraviolet radiation on Mdm2SNP309 skin cancer risk 
Rational 
Previous research conclusively showed that the SNP309G allele is the ‘at risk’ 
allele for tumor risk [107, 119]. My previous experiments show Mdm2SNP309G/G mice 
exhibit increased cancer risk after exposure to low-dose ionizing radiation compared to 
Mdm2SNP309T/T mice. To further examine the influence of other environmental factors on 
the SNP309G allele and cancer risk, we investigated the influence of ultraviolet radiation 
on Mdm2SNP309 mice and skin cancer. Ultraviolet (UV) radiation is the primary 
environmental cause of skin cancer in humans [136]. UVB causes pro-mutagenic DNA 
lesions that result in bulky DNA adducts composed mostly of thymine dimers and 6,4-
photoproducts [137]. Nucleotide excision repair (NER) removes DNA damage induced 
by UVB by recognizing damage site and removes short single-stranded DNA segment 
that contains the lesion [138]. Furthermore, exposure to UVB radiation induces 
intracellular reactive oxygen species, which elicit a robust p53 response [139, 140] and 
leads to skin cancer development [141]. The C57BL/6 strain mouse is resistant to skin 
tumors [142], and thus is not an adequate model. However, the FVB mouse strain is 
susceptible to insult-induced skin tumorigenesis and has been characterized as a model 
for studying progressive squamous cell carcinoma [143]. Thus, we hypothesized that 
UVB radiation would exacerbate tumor development in Mdm2SNP309G/G mice compared to 
Mdm2SNP309T/T mice in an FVB background strain. To this end, we generated cohorts of 
Mdm2SNP309T/T and Mdm2SNP309G/G mice in an FVB background strain (+99%), treated 
them with UVB radiation, and followed them for tumor formation. 
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Note: section 2.2 was conducted in a collaborative effort with Dr. David G. Johnson’s 
laboratory.  
Ultraviolet radiation preferably attenuates p53 activity in epidermis tissue from 
Mdm2SNP309T/T mice compared to Mdm2SNP309G/G mice 
I first characterized the effect of ultraviolet radiation (UVB) on Mdm2 levels and 
p53 activity in keratinocytes of Mdm2SNP309T/T and Mdm2SNP309G/G mice in an FBV strain 
background. To test the effects of UVB on Mdm2 in keratinocytes, primary keratinocytes 
were treated with a single dose of UVB (100mJ/cm2) and RNA was isolated. Primary 
keratinocytes were isolated from Mdm2SNP309G/G and Mdm2SNP309T/T mouse epidermis and 
RNA was extracted from the cells. In contrast to studies in the spleen (Figure 3), primary 
keratinocytes from Mdm2SNP309T/T mice showed relatively higher Mdm2 basal levels as 
compared to keratinocytes from Mdm2SNP309G/G mice (Figure 14). Consistent with the 
non-treated samples, keratinocytes isolated from Mdm2SNP309T/T mice showed greater than 
two-fold higher Mdm2 levels (p=0.001) 24 hours post UVB treatment compared to 
Mdm2SNP309G/G keratinocytes (Figure 14).  
To test the effects of UVB on p53 activity in skin tissue, the epidermis from 6-
week old Mdm2SNP309G/G and Mdm2SNP309T/T mice were treated with a single dose of UVB 
(100mJ/cm2), a dose previously shown to activate acute p53 response in skin tissue [144], 
and analyzed for p21 protein expression to evaluate p53 activity. Consistent with the 
elevated Mdm2 expression levels in keratinocytes from Mdm2SNP309T/T compared to 
Mdm2SNP309G/G mice after UVB treatment, Mdm2SNP309G/G keratinocytes displayed a 
significantly higher number of cells staining positive for p21 (p=0.019) compared to 
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Mdm2SNP309T/T keratinocytes (Figure 15). These data show that Mdm2 expression is 
greater in skin from Mdm2SNP309T/T mice compared to Mdm2SNP309G/G mice and that UVB 
irradiation elevates Mdm2 levels more in skin tissue of Mdm2SNP309T/T mice compared to 








Figure 14. Mdm2 expression in Mdm2SNP309 keratinocytes 24h post UV radiation. 
RT-qPCR analysis of Mdm2 expression in keratinocytes from Mdm2SNP309T/T and 
Mdm2SNP309G/G mice 24 hours post UV radiation (100mJ/cm2). Three mice per genotype 
were analyzed. The average expression of untreated (T/T) keratinocytes was normalized 
to 1 for comparison. Keratin 14 expression (housekeeping gene) was used as internal 








Figure 15. Expression analysis of p53 targets in Mdm2SNP309 skin tissues 24h post 
UVB. Protein expression analysis of p21 in skin tissues of Mdm2SNP309T/T and 
Mdm2SNP309G/G mice 24 hours post UV radiation (100mJ/cm2). Three mice per genotype 
were analyzed. The graph represents the percent of cells positive for p21 protein 
expression. UVB, ultraviolet radiation; Mdm2SNP309T/T, T/T; Mdm2SNP309G/G, G/G. 
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Ultraviolet radiation exacerbates squamous cell carcinoma development in 
Mdm2SNP309T/T mice compared to Mdm2SNP309G/G mice 
To examine the long-term effects of UVB exposure on skin cancer risk, a cohort 
of Mdm2SNP309G/G and Mdm2SNP309T/T mice in an FVB background was generated and 
treated with an established UVB regimen [144] (UVB radiation three times per week for 
30 weeks) and monitored for spontaneous tumor development. The cohort was observed 
for 40 weeks because most mice, independent of genotype, acquire squamous cell 
carcinoma within this time frame. Tumor-free survival analysis of UVB-treated mice also 
showed that Mdm2SNP309T/T mice exhibit significantly sooner onset to UVB-induced 
squamous cell carcinoma than Mdm2SNP309G/G mice (p<0.0001) (Figure 16) with a median 
survival of 28 weeks compared to 36 weeks. Non-UV treated FVB mice did not develop 
skin tumors [145]. Further assessment of the tumor-free survival stratified by gender 
show that male Mdm2SNP309G/G mice were significantly delayed in tumor development 
(p<0.0001) compared to the other groups (Figure 16). Moreover, Mdm2SNP309G/G female 
mice develop UVB-induced skin SCC at a later age compared to female Mdm2SNP309T/T 
mice. The data showed that the long-termed effects of UVB treatment increased death of 
Mdm2SNP309T/T mice through squamous cell carcinoma development compared to 









Figure 16. Tumor-free survival of UVB-irradiated SNP309 mice. Numbers reflect 
mouse numbers in the cohorts. The parentheses represent the environmental exposure. 
The G/G UVB group reached median tumor-free survival of 36 weeks compared to T/T 
group, which reach 28 weeks. Tumor free survival by gender shows that G/G males are 
more resistant to tumors compared to the rest of the groups (p<0.0001). The statistical 
differences in the curves were measured using a Log-rank test. UVB, ultraviolet 
radiation; Mdm2SNP309T/T, T/T; Mdm2SNP309G/G, G/G; M= male, F= female. 
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Ultraviolet radiation increases Mdm2 expression in a tissue-dependent manner in 
Mdm2SNP309 mice  
  UV treatment led to a dampened p53 response and shorter tumor latency in 
Mdm2SNP309T/T mice compared to Mdm2SNP309G/G mice in an FVB mouse background 
strain. These data are in contrast to the Mdm2SNP309 IR treatment results, which were 
conducted in a C57BL/6 mouse strain background. These data suggest that either the type 
of DNA damage, cell type, or mouse strain account for the differences in tumorigenesis. 
Previous data show that fibroblasts harvested from Mdm2SNP309T/T and Mdm2SNP309G/G 
mice in C57BL/6 strain background show higher basal Mdm2 levels in Mdm2SNP309G/G 
than in Mdm2SNP309T/T genotype [119]. Therefore, we hypothesized that fibroblasts 
harvested from Mdm2SNP309G/G mice in FVB strain would exhibit higher Mdm2 levels 
compared to Mdm2SNP309T/T mice after UVB treatment. Thus, primary fibroblasts from 
Mdm2SNP309T/T and Mdm2SNP309G/G FVB mice were harvested were treated with a single 
dose of UVB (100mJ/cm2) and prepared for RNA isolation. The results show 1.9-fold 
higher (p=0.001) increase in Mdm2 expression 24 hours post UVB treatment in 
Mdm2SNP309G/G compared to Mdm2SNP309T/T fibroblasts (Figure 17), suggesting that the 








Figure 17. Mdm2 expression in Mdm2SNP309 primary fibroblasts cells from FVB mice 
24h post UV radiation. RT-qPCR analysis of Mdm2 expression in the fibroblasts from 
Mdm2SNP309T/T and Mdm2SNP309G/G mice 24 hours post UV radiation (100mJ/cm2). Three 
mice per genotype were analyzed. The average expression of untreated (T/T) fibroblasts 
was normalized to 1 for comparison. GAPDH expression (housekeeping gene) was used 
as internal control. UVB, ultraviolet radiation; Mdm2SNP309T/T, T/T; Mdm2SNP309G/G, G/G.  
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Epidermal tissue from Mdm2SNP309T/T mice exhibit higher Mdm2 expression 
independent of insult compared to Mdm2SNP309G/G mice 
Benzo(a)pyrene (B(a)P) is a tobacco-related carcinogen that causes DNA damage 
[146]. To determine if the differences in skin tumor onset are limited to UVB insult, we 
next investigated the effects of B(a)P on p53 activity in the skin of our mice. The 
epidermis of Mdm2SNP309G/G and Mdm2SNP309T/T mice was treated with either acetone 
(control) or B(a)P, and total RNA was isolated 24-hour post treatment. Mdm2 mRNA 
levels were higher in Mdm2SNP309T/T mice compared to Mdm2SNP309G/G mice after B(a)P 
treatment. However, the differences were not statistically significant (Figure 18).  
To examine tumor risk following B(a)P exposure, we treated Mdm2SNP309G/G and 
Mdm2SNP309T/T mice to an established regimen of 317 nmol of B(a)P once a week for 30 
weeks [146] and monitored mice for spontaneous tumor formation. Tumor-free survival 
showed that B(a)P treated Mdm2SNP309T/T mice were more susceptible than Mdm2SNP309G/G 
mice (p<0.0001) (Figure 19) with a median survival of 22 weeks compared to 25 weeks, 
respectively. Further assessment of the tumor-free survival data showed that the 
difference was primarily due to gender (Figure 20). Tumor development in male 
Mdm2SNP309G/G mice was significantly delayed (p<0.0001) compared to the other groups. 
We, therefore, revisited the Mdm2 expression levels in the epidermis of Mdm2SNP309G/G 
and Mdm2SNP309T/T male mice. Similarly, Mdm2 mRNA levels were significantly lower 
(p=0.03) in the epidermis of male Mdm2SNP309G/G mice compared to male Mdm2SNP309T/T 
mice 24-hour post B(a)P treatment, but there were no significant differences between 
female mice (Figure 21). Moreover, epidermal keratinocytes in skin samples from male 
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Mdm2SNP309G/G mice displayed a significantly higher number of cells staining positive for 
p21 (p=0.04) as compared to Mdm2SNP309T/T keratinocytes after B(a)P treatment (Figure 
22). Altogether, the data show that keratinocytes from male Mdm2SNP309G/G mice 
exhibited significantly lower Mdm2 expression and increased p53 activity in 
Mdm2SNP309G/G mice compared to Mdm2SNP309T/T mice in response to B(a)P insult. Thus, 
Mdm2SNP309G/G mice, particularly males, are more resistant to developing skin SCC in 























Figure 18. Mdm2 expression in Mdm2SNP309 epidermis tissues 24h post B(a)P 
treatment. RT-qPCR analysis of Mdm2 expression in epidermis tissues from 
Mdm2SNP309T/T and Mdm2SNP309G/G mice 24 hours post B(a)P treatment. Six mice per 
genotype represent the analysis. The average expression of control (Acetone) T/T 
epidermis was normalized to 1 for comparison. Keratin 14 expression (housekeeping 
gene) was used as internal control. B(a)P, Benzo(a)pyrene; Mdm2SNP309T/T, T/T; 






























Figure 19. Tumor-free survival of B(a)P treated Mdm2SNP309 mice. Numbers reflect 
mouse numbers in the cohorts. The parentheses represent the environmental exposure. 
The G/G B(a)P group reached median tumor-free survival of 25 weeks compared to T/T 
group, which reached 22 weeks. The statistical differences in the curves were measured 









Figure 20. Tumor-free survival of B(a)P treated Mdm2SNP309 mice separated by 
gender. Numbers in parentheses reflect mouse numbers in the cohorts. The statistical 
differences in the curves were measured using a Log-rank test. B(a)P, Benzo(a)pyrene; 









Figure 21. Mdm2 expression in epidermis tissues of male and female Mdm2SNP309 
mice 24h post B(a)P treatment. RT-qPCR analysis of Mdm2 expression in the 
epidermis from male and female Mdm2SNP309T/T and Mdm2SNP309G/G mice 24 hours post 
B(a)P treatment. Three mice per genotype represent the analyses. The average expression 
of control (Acetone) T/T epidermis was normalized to 1 for comparison. Keratin 14 
expression (housekeeping gene) was used as internal control. B(a)P, Benzo(a)pyrene; 









Figure 22. Expression analysis of p53 targets in male SNP309 skin tissues 24h post 
B(a)P treatment. Protein expression analysis of p21 by IHC in skin tissues from male 
Mdm2SNP309T/T and Mdm2SNP309G/G mice 24 hours post B(a)P treatment. Three mice per 
genotype represent the analysis, and the number of positive cells per field of view was 
counted in three sections per mouse. The graph represents the percent of cells positive for 




Interim summary  
The influence of UV exposure led to a dampened p53 response and shorter tumor 
latency in Mdm2SNP309T/T mice compared to Mdm2SNP309G/G mice, in contrast to IR 
treatment. The evaluation of the Mdm2 expression in different tissues (keratinocytes and 
fibroblasts) after UVB treatment suggests that the cell-type accounts for the differences in 
tumorigenesis. Furthermore, B(a)P treatment in the skin of SNP309 mice exhibit shorter 
tumor latency in Mdm2SNP309T/T mice compared to Mdm2SNP309G/G mice, consistent with 
UVB experiment. Thus exposure to skin insult predisposes Mdm2SNP309T/T mice to SCC 














Investigating the role of the SNP309G allele in Mdm2 regulation in a tissue-
dependent manner 
Thus far, the data suggest that the influence of environmental factors on SNP309 
cancer risk in mice is cell-type-dependent. Therefore, I hypothesized that the Mdm2 
regulation in SNP309 mice occurs in a tissue-dependent manner. To this end, I harvested 
tissues from SNP309 mice and evaluated the Mdm2 basal expression in different tissues. 
Furthermore, I employed in silico analysis to examine transcription factor candidates that 
may differentially bind to the MDM2 P2 promoter in a tissue-specific manner. Finally, I 
utilized tissues from SNP309 mice to investigate the possible SNP309-dependent 
mechanism(s) of Mdm2 regulation in different tissues.  
 
Mdm2 expression is tissue-dependent in Mdm2 SNP309 mice 
To address the opposite differences in vulnerability to cancer risk after exposure 
to environmental factors, I evaluated the Mdm2 basal expression in different tissues 
harvested from Mdm2SNP309G/G and Mdm2SNP309T/T mice in a C57BL/6 background. Mdm2 
basal levels vary in different tissues in an SNP-dependent manner (Figure 23). Mdm2 
mRNA levels in the thymus (the origin of T-cell lymphomas) of Mdm2SNP309G/G mice are 
statistically higher (p=0.04) than in Mdm2SNP309T/T mice. Conversely, keratinocytes, the 
cell of origin for SCC, in Mdm2SNP309T/T mice exhibit significantly higher Mdm2 mRNA 
levels (p=0.001) than keratinocytes in Mdm2SNP309G/G mice. Similarly, epidermis, a source 
of keratinocytes, isolated from Mdm2SNP309T/T FVB mice show significantly higher Mdm2 
basal levels (p=0.04) compared to Mdm2SNP309G/G FVB mice (Figure 24). Thus, 
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keratinocytes from Mdm2SNP309G/G mice exhibit lower Mdm2 basal levels compared to 
keratinocytes from Mdm2SNP309T/T mice independent of mouse strain. One other tissue 
showed significant differences in Mdm2 levels; the heart tissue exhibited significantly 
higher Mdm2 mRNA levels (p=0.006) in Mdm2SNP309G/G mice than in Mdm2SNP309T/T mice 
(Figure 23). Further investigation showed that other tissues exhibited significant 







Figure 23. Mdm2 basal expression in tissues of SNP309 mice in C57BL/6 strain. RT-
qPCR analysis of Mdm2 expression in different tissues from Mdm2SNP309T/T and 
Mdm2SNP309G/G mice. Eight mice per genotype in each tissue type were analyzed. RplpO 























Figure 24. Mdm2 basal expression in epidermis of SNP309 mice in FVB strain. RT-
qPCR analysis of Mdm2 expression in the epidermis from Mdm2SNP309T/T and 
Mdm2SNP309G/G mice. Six mice per genotype were analyzed. The average expression of 
T/T epidermis was normalized to 1 for comparison. Keratin 14 expression (housekeeping 








Figure 25. Mdm2 basal expression in SNP309 mouse by gender. RT-qPCR analysis of 
Mdm2 expression in the different tissues from Mdm2SNP309T/T and Mdm2SNP309G/G mice 
separated by gender. Four mice per genotype (per gender) in each tissue type were 
analyzed. The average expression of T/T tissues was normalized to 1 for comparison. 
RplpO expression (housekeeping gene) was used as internal control. Mdm2SNP309T/T, T/T; 
Mdm2SNP309G/G, G/G; M= male, F= female; * = p<0.01, ** = p<0.001. 
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The identification of E2F family members as transcriptional regulators of the Mdm2 
gene  
To investigate the mechanism by which the SNP309 alleles regulate Mdm2 
expression in a tissue-specific manner, we first interrogated potential transcription factor 
binding to the SNP309 allele. Analyses of the ENCODE ChIP-seq database [147] in 
genome browser (https://genome.ucsc.edu) showed that transcriptional repressors E2F4 
and E2F6 were candidates because of their binding proximity to SNP309 (Figures 26, 
27). Additionally, previous studies associated these repressors as key regulators of 
keratinocyte proliferation [148]. The cell lines utilized in the ENCODE ChIP-seq 
experiments for E2F4 and E2F6 were MCF10A and K562, respectively. Sequence 
analysis of these cell lines showed that MCF10A cells harbor a homozygous SNP309T 









Figure 26. Predicted SP1 & E2F binding sites in the MDM2 P2 promoter proximal 











Figure 27. ENCODE ChIP-seq transcription factor binding analysis proximal to 










Figure 28. Sequencing MCF10A and K562 cell lines for the Mdm2 SNP309. The 
analysis was conducted through Sanger sequencing. MCF10A cell line harbors MDM2 
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Transcriptional repressor E2F6 negatively regulates Mdm2 expression in SNP309G 
cells but not in SNP309T cells 
To examine if E2F4 and E2F6 regulate Mdm2 expression in an SNP309 allele-
dependent manner, we generated MEFs from Mdm2SNP309G/G and Mdm2SNP309T/T C57BL/6 
mice and transfected them with plasmids expressing GFP and either E2F4, E2F6, or SP1, 
a transcriptional activator that increases Mdm2 expression in Mdm2SNP309G/G cells. Cells 
were sorted based on GFP expression, and GFP positive cells were analyzed via RT-
qPCR. As expected, sorted cells expressing GFP and Sp1 preferentially increased Mdm2 
expression in SNP309G MEFs (p<0.001) (Figure 29). E2F4 transfection increased Mdm2 
expression slightly in SNP309T cells, but there were no significant differences between 
genotypes (Figure 30). E2F6 transfection statistically repressed transcription of Mdm2 in 
SNP309G MEFs compared to SNP309T MEFs (p<0.001) (Figure 31). To test the 
efficiency of transfections, we performed RT-qPCR on FGF21 and BRCA1 (known 
targets of Sp1 and E2F6, respectively) and there were no significant differences in 
expression between SNP309T MEFs compared to SNP309G MEFs (Figure 32). Finally, I 
examined protein levels of SP1 and E2F6 in thymus and keratinocytes harvested from 
Mdm2SNP309G/G and Mdm2SNP309T/T mice and showed that SP1 is expressed in thymus and 
not detectable in keratinocytes and vice versa, E2F6 is clearly expressed in keratinocytes 









Figure 29. Mdm2 mRNA expression in MEFs transfected with SP1. Primary MEF’s 
from SNP309 mice were transiently transfected with 6ug of plasmids expressing SP1 and 
FACS sorted with GFP. Expression levels are normalized to that of empty vector 
(control) samples. Statistical significance was determined by Two-way ANOVA; 










Figure 30. Mdm2 mRNA expression in MEFs transfected with E2F4. Primary MEF’s 
from SNP309 mice were transiently transfected with 6µg of plasmids expressing E2F4 
and FACS sorted with GFP. Expression levels are normalized to that of empty vector 
(control) samples. Statistical significance was determined by Two-way ANOVA; 












Figure 31. Mdm2 mRNA expression in MEFs transfected with E2F6. Primary MEF’s 
from SNP309 mice were transiently transfected with 6ug of plasmids expressing E2F6 
and FACS sorted with GFP. Expression levels are normalized to that of empty vector 
(control) samples. Statistical significance was determined by Two-way ANOVA; 











Figure 32. Mdm2 mRNA expression in MEFs transfected with SP1 or E2F6. Primary 
MEF’s from SNP309 mice were transiently transfected with 6µg of plasmids expression 
SP1 or E2F6 and FACS sorted with GFP. Expression levels are normalized to that of 
empty vector (control) samples. Statistical significance was determined by Two-way 











Figure 33. Protein analyses in thymi and keratinocytes of SNP309 mice. Western blot 
analysis of basal levels of SP1 and E2F6 proteins. Two tissues per genotype were 
representative of the analysis. GAPDH protein expression was used as a control. M, 




Transcriptional repressor E2F6 preferably binds to the Mdm2 P2 promoter of 
SNP309G keratinocytes compared to SNP309T keratinocytes  
We next examined the binding specificity of E2F6 to the Mdm2-P2 promoter in 
keratinocytes harvested from SNP309 mice by performing chromatin 
immunoprecipitation assays (ChIP). We isolated primary keratinocytes from 
Mdm2SNP309G/G and Mdm2SNP309T/T newborn pups. ChIP with an E2F6 antibody and 
subsequent RT-qPCR analysis showed that E2F6 binds more significantly (p<0.0001) to 
the Mdm2-P2 promoter in keratinocytes of SNP309G compared to SNP309T (Figure 34). 
Binding of E2F6 to the control BRCA1 promoter (an established target of E2F6) showed 














Figure 34. E2F6 ChIP analysis of the MDM2 P2 promoter in keratinocytes of 
Mdm2SNP309T/T and Mdm2SNP309G/G mice. E2F6 ChIP assays for the BRCA1 promoter in 
keratinocytes was used as positive control. A sequence downstream of the Mdm2 
promoter not thought to bind E2F6 was used as a negative control. Statistical analysis 




Interim summary   
Mdm2 basal expression in tissues from Mdm2SNP309 mice revealed contrasting 
differences in expression. Keratinocytes from Mdm2SNP309T/T mice exhibit higher Mdm2 
basal expression compared to Mdm2SNP309G/G mice in C57BL/6 and FVB strains. ChIP-
seq data from ENCODE show that transcriptional repressor E2F6 binds proximal to the 
MDM2 P2 promoter. Transfection experiments in cells harvested from  Mdm2SNP309 mice 
show that E2F6 lowers Mdm2 expression in Mdm2SNP309G/G tissues, but does not affect 
Mdm2SNP309T/T tissues. Finally, ChIP with an E2F6 antibody and subsequent RT-qPCR 
analysis showed that E2F6 binds more significantly to the Mdm2-P2 promoter in 
keratinocytes of Mdm2SNP309G/G mice compared to Mdm2SNP309T/T keratinocytes. 
Collectively, these data show that the SNP309G regulates Mdm2 basal expression in a 





























Chapter 3. Materials and Methods 
Generation of homozygous Mdm2SNP309T/T and Mdm2SNP309G/G mice. (Resource 
previously available in the laboratory) 
MD Anderson Cancer Center Institutional Animal Care and Use Committee 
approved all protocols on mouse experiments, and these were conducted in compliance 
with the guidelines of the United States Animal Welfare Act and the National Institutes 
of Health. The Mdm2SNP309G/G and Mdm2SNP309T/T mouse models were generated in our 
laboratory and had been previously described [119]. To generate Mdm2SNP309G/G and 
Mdm2SNP309T/T mice in FVB background strain, Mdm2SNP309G/G and Mdm2SNP309T/T mice in 
C57BL/6 background strains were backcrossed for five generations to FVB by the 
Johnson laboratory. 
Mouse genotyping analysis 
Tissues were collected from mice, either tails or ear punch, and were first 
genotyped for Mdm2 alleles using a previously described protocol [66, 149]. The forward 
primer (5'- GCATTAGAGAGTGGTCACTGCGAC-3’) reverse primer (5’- 
GAACAGTGATAGAACATCATGTCAC-3’) were used. PCR conditions: 95°C for 5 
minutes for preheating, followed by 95°C 1 minute, 54°C 45 seconds, 72°C 1 minute, 
(steps 2-4 were repeated for 40 cycles), and 72C for 8 minutes for elongation. Bands 
were identified at 150 base pairs. After genotyping, DNA from Mdm2SNP309G/G and 
Mdm2SNP309T/T mice were randomly sequenced using Sanger-based DNA sequencing to 
confirm the presence of the G or T nucleotide using primers within the MDM2 P2 
promoter using forward  (5’-GGATTTCGGACGGCTCTCG-3’) and reverse (5’-
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CGCGCAGCGTTCACACTAG-3’) primers. The sequencing was performed by the 
Sequencing and Microarray Facility (SMF) at the University of Texas M.D. Anderson 
Cancer Center using the forward and reserve primers.  
 
Environmental stress treatments 
In the ionizing radiation study, we generated cohorts of Mdm2SNP309G/G and 
Mdm2SNP309T/T mice in the C57BL/6 strain background and treated the cohorts with 1Gy 
ionizing radiation two days after birth as a model for environmental stress. Cohorts of 
non-treated Mdm2SNP309G/G and Mdm2SNP309T/T mice were also generated as controls. I 
monitored daily spontaneous tumor susceptibility in treated and non-treated cohorts and 
mice were sacrificed upon tumor formation. 
For the skin carcinogenesis study, we generated cohorts of Mdm2SNP309G/G and 
Mdm2SNP309T/T mice in the skin tumor prone FVB background strain and treated the cohort 
with a skin carcinogenesis regimen, including UVB and B(a)P, as previously described  
[144, 150]. Non-treated Mdm2SNP309G/G and Mdm2SNP309T/T mice were used as controls.  
UVB regimen 
The dorsal skins of young adult (six to eight week old) Mdm2SNP309G/G and 
Mdm2SNP309T/T mice were shaved and one day later exposed to gradually increasing doses 
of UVB radiation (100- 341 mJ/cm2) three times per week for 30 weeks. Mice were 




The dorsal skins of young adult Mdm2SNP309G/G and Mdm2SNP309T/T mice were 
shaved and one day later B(a)P dissolved in acetone (317 nmol) was applied to the 
shaved area.  This treatment continued once a week for 30 weeks.  Mice were monitored 
for an additional ten weeks before all mice were sacrificed.  
 
Histopathology and Immunohistochemistry 
Histological preparation and immunohistochemistry (IHC) were conducted as a 
collaborative effort between Dr. Lozano and Dr. Johnson's laboratories.  
Dr. Lozano’s laboratory 
Mouse tissues were harvested from euthanized mice and washed in cold 
phosphate buffered saline (PBS) and fixed in 10% formalin for 48 hours. Histological 
processing and hematoxylin and eosin (H&E) were performed by the Department of 
Veterinary Medicine at the University of Texas M.D. Anderson Cancer Center. Tissues 
were sectioned into slices with 6 µM thickness. Immunohistochemistry was performed on 
paraffin-embedded tissues as previously described [151], using antibodies for cleaved 
caspase-3 (1:200, Cell Signalling Technology, Asp 175), CD3 (1:100, Abcam, ab5690), 
B220 (1:100, BD Pharmigen, 530286) and p21-WAF1-Cip1 (1:200, Dako, M7202). Stain 
sections were detected with Vectastain Elite ABC Reagent and Vector DAB substrate 
(Vector Laboratories, PK-6100) 
Dr. Johnson’s laboratory 
Tissue processing and immunohistochemistry were performed by the MD Anderson 
Cancer Center, Science Park Histology Core. Briefly, dorsal skin samples were fixed in 
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10% formalin for 24 h, paraffin-embedded, sectioned and stained for p53 (Novocastra 
#NCL-p53-CM5p). Digital images of stained sections were captured using the Aperio 
ScanScope CS slide scanner and the numbers of positive cells in the epidermis were 
counted using the manufacturer’s GENIE software (Aperio Technologies, Vista, CA). 
 
Western Blot analysis  
Protein lysates were prepared by lysing thymi or keratinocytes from SNP309 mice 
in NP-40 buffer. Protein estimation was carried out with BCA (Pierce #23225). One 
hundred micrograms of lysate were resolved on 10% SDS-PAGE and transferred to 
nitrocellulose membranes and immunoblotted with antibodies against SP1 (1:200; Santa 
Cruz, #sc-59), E2F6 (1:200; Santa Cruz #E-20), and GAPDH (1:1000; Abcam #ab9485). 
Western blots were repeated at least three times with biological replicates. The 
membranes were incubated with IRDye@800 conjugated goat anti-rabbit IgG (1:10,000; 
LI-COR, #926-3211) or IRDye@680LT conjugated donkey anti-mouse IgG (1:10,000; 
LI-COR, #926-68022) the membranes were scanned with ODYSSEY CLx Infrared 
Imaging System.  
 
Real-Time RT-PCR  
Fresh tissues were necropsied from mice and flash frozen. Total RNA was 
isolated using TRIZOL reagent (Invitrogen, 15596-026) following the manufacturer’s 
instructions. The RNA was treated with DNase I (Roche, 0416728-001) and reverse 
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transcribed using the product protocol (GE Healthcare, 27-9261). Real-Time RT-PCR 
using SYBR green (BioRad, 1725270) was performed on a 7900HT Fast Real-time PCR 
system (Applied Biosystems) using a method previously described [152]. Expression was 
normalized to Rplp0. 
 
Primary cell cultures  
Keratinocytes 
Primary keratinocytes were isolated from the epidermis of two-day-old 
Mdm2SNP309G/G and Mdm2SNP309T/T pups. The pups were decapitated and washed with PBS 
and rinsed in 70% ethanol. The pups were skinned, and the skin layer was digested with 
dispase (1500 unit/ml, Becton Dickinson, 354235) overnight at 4oC. After digestion, the 
epidermis was isolated, minced and vigorously shaken in DMEM containing 10% FBS 
before it was passed through a 70 µm mesh filter. To improve yields and control for 
sample variability, we pooled epidermis from multiple mice harboring the same 
genotype. We plated 1X107 cells in 10 cm dishes in Waymouth’s MB752/1 media (Life 
Technologies, 11220-035) for 3h, and then replaced the media with KGM-2 media 
(Lonza, CC-3108). Keratinocytes were ready for experiments after three days. 
Mouse embryonic fibroblasts (MEFs) 
MEFs were harvested from 13.5-day embryos of Mdm2SNP309G/G and Mdm2SNP309T/T 
genotype as previously described [76]. MEFs were cultured in Dulbecco's modified 
Eagle's medium (Thermo Fisher, 11965-092) supplemented with 10% FBS and 
penicillin-streptomycin (100 IU/ml, 100 ugs/ml respectively). Only low-passage MEFs 
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were used for experiments (< P4). Early passage MEFs were transfected with seven µg of 
pCMV-GFP vector containing E2F6 cDNA, SP1 cDNA, or empty vector using 
Lipofectamine 3000 reagent (Sigma, L3000015). Forty-eight hours later, GFP-positive 
cells were sorted by FACS and RNA was extracted for RT-PCR analysis.  
 
Chromatin immunoprecipitation assay 
The Chromatin immunoprecipitation assay was executed as previously described 
[153]. The E2F6 Antibody  (Santa Cruz Biotechnology, E-20) was previously 
characterized for chromatin immunoprecipitation [154]. The chromatin was cross-linked 
with 37% formaldehyde for 10 minutes, and the fixation was terminated by the addition 
of 2M glycine. The cells were harvested in SDS buffer (100 mM NaCl; 50 mM Tris-HCl, 
pH 8.1; 5 mM EDTA, pH 8.0; 0.02% NaN3; and 0.5% SDS, plus protease inhibitors) and 
pelleted. The pellets were resuspended in 0.75 ml (per T150 flask) ice-cold 
immunoprecipitation (IP) buffer (100 mM Tris, pH 8.6; 0.3% SDS; 1.7% Triton X-100; 5 
mM EDTA) and sonicated by pulsing 5 times for 20 s at power setting 3  and 100% duty 
cycle on a Branson Sonifier 450. Sonication average length of 300 to 1,000 bp was 
confirmed by agarose gel electrophoresis. The Bradford protein assay was performed as 
previously described [153] to quantify the immunoprecipitation concentration and 
aliquots of 1.5mg of protein were prepared in IP buffer. The aliquots were pre-cleared 
with 25µl of salmon sperm/protein A agarose beads (Millipore SIGMA, 16-157C). 25ul 
of each aliquot was saved as an input control. The primary antibody (2 µg) was added 
overnight at 4°C. Salmon sperm/protein A agarose was added to the immune complexes. 
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The input controls and washed immune complex pellets were resuspended in 250µl of 1% 
SDS, 0.1 M NaHCO3, and the samples were incubated overnight at 65°C to elute the 
immune complexes and to reverse the cross-links. The digestion with proteinase K was 
performed as previously described [153] and the samples were resuspended in 300µl of 
H2O. Real-time PCR was performed as previously described [152]. Primers were 
designed using primer express software (http://home.appliedbiosystems.com). Data was 
presented as percentages of the total, calculated exactly as previously published [152].  
 
Statistical analysis 
All comparisons were analyzed using GraphPad Prism version 6.00 (GraphPad 
Software, La Jolla California USA). Gene expression analysis comparing untreated to 
treated samples was determined by two-way analysis of variance (ANOVA), and the 
comparison of basal expression between the two genotypes was determined by student's 
t-test. Tumor-free survival was determined using Log-Rank test and differences in tumor 
spectrum and tumor multiplicity with Fisher's exact test. A p-value of <0.05 was 

























Chapter 4. Discussion and Future Directions 
Discussion  
Functional polymorphisms alter gene function and can lead to disease risk. 
Environmental factors can have synergistic effects on disease-associated SNPs and 
exacerbate the outcome; however cooperative mechanisms between functional 
polymorphisms and environmental factors have not been well defined. In my thesis work, 
I utilized a well-known functional polymorphism involved in the p53 pathway, SNP309, 
to investigate gene-environment interactions in modulating tumor susceptibility. Previous 
data investigated the influence of the SNP309G on tumor risk. Mouse models harboring 
the Mdm2SNP309 alleles were genetically engineered and examined for tumor 
susceptibility. The data show that Mdm2SNP309G/G mice are more susceptible to 
spontaneous tumor formation and exhibit a significantly lower overall survival compared 
to Mdm2SNP309T/T mice [119]. Furthermore, tissues from Mdm2SNP309G/G mice show 
significantly higher Mdm2 expression and exhibit decrease apoptotic response compared 
to Mdm2SNP309T/T tissues. Consequently, the p53 pathway is attenuated in tissues from 
Mdm2SNP309G/G mice. Thus, these data determined that the SNP309G allele has a direct 
impact on tumor risk [119]. To study the effects of environmental factors and the 
SNP309G allele in tumor risk, I challenged Mdm2SNP309T/T and Mdm2SNP309G/G mice with 
established environmental stresses that promote cancer risk and affect the p53 pathway. 
Furthermore, these models are relevant to human health: people are consistently exposed 
to low dose IR via cosmic rays and medical imaging procedures [133], UV from the sun 
[139], and the B(a)P carcinogen from smoking [155].  
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My results show that SNP309G allele exacerbated tumor risk in Mdm2SNP309G/G 
mice compared to Mdm2SNP309T/T mice after low-dose IR treatment. These results support 
previous data [119], which show that the Mdm2SNP309G/G mice have increased 
susceptibility to tumors compared to Mdm2SNP309T/T mice, affirming that SNP309G is an 
‘at risk’ allele for spontaneous tumor formation. In contrast, Mdm2SNP309T/T mice exhibit 
increased risk of skin squamous cell carcinoma compared to Mdm2SNP309G/G mice after 
UVB or B(a)P treatment. Overall, these results suggest that environmental factors and 
cellular factors cooperate to promote cancer risk in a tissue-dependent manner.  
 
Mdm2 expression differences in tumor-prone tissues  
The differences in tumor risk between Mdm2SNP309T/T and Mdm2SNP309G/G mice 
suggested tissue-specific differences in their regulation of the p53 pathway. To further 
understand these conflicting results, I first evaluated p53 activity in response to insult in 
tumor-prone tissues. In the low-dose IR study, spleen and thymus from Mdm2SNP309G/G 
mice show increased Mdm2 expression and dampened p53 activity post-IR treatment 
compared to irradiated tissues from Mdm2SNP309T/T mice and to non-irradiated mice. 
Furthermore, the data showed that Mdm2SNP309G/G mouse lymphatic tissues exhibit a delay 
in activation of apoptosis compared to Mdm2SNP309T/T after low-dose IR. Previous data 
show that Akt signaling pathway delays p53-mediated apoptosis [156], suggesting 
crosstalk between p53, Mdm2, and Akt pathways affect program cell death [157].  
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In contrast, both UVB and B(a)P skin carcinogenesis models in an FVB 
background demonstrated the opposite effect and highlighted increased Mdm2 expression 
and attenuated p53 activity in the epidermal skin cells of Mdm2SNP309T/T mice compared to 
Mdm2SNP309G/G mice. These contrasting results can be explained by the opposing 
differences in Mdm2 basal expression in lymphatic and epidermal skin tissues, thus 
resulting in tissue-specific differences in steady state levels of p53 and transactivation of 
p53 targets in response to insult.  
The IR and UVB/B(a)P experiments were performed in C57BL/6 and FVB 
background strains, respectively, exposing the possibility that observed differences were 
strain-specific. Thus, I investigated the effects of mouse strain on Mdm2 expression of 
keratinocytes from Mdm2SNP309 mice in C57BL/6 and FVB background strains. The data 
showed that keratinocytes from Mdm2SNP309T/T mice exhibit higher Mdm2 basal 
expression levels compared to Mdm2SNP309G/G mice independent of mouse strain. 
Moreover, fibroblasts from Mdm2SNP309G/G FVB mice showed relatively higher Mdm2 
basal expression levels compared to fibroblasts from Mdm2SNP309T/T FBV mice. These 
data are consistent with previous experiments conducted in C57BL/6 mice. Thus, mouse 
strain did not affect SNP309-dependent Mdm2 regulation in epidermal skin tissue and 
fibroblasts.  
Another factor that we investigated was the effect of DNA damage on Mdm2 
expression on different cell-types from Mdm2SNP309 mice. Exposure to UVB further 
increased Mdm2 expression levels of keratinocytes from Mdm2SNP309T/T mice compared to 
Mdm2SNP309G/G keratinocytes. Thus, we examined the effects of UVB on fibroblast cells 
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from Mdm2SNP309 FVB mice. The data show fibroblasts from Mdm2SNP309G/G FVB mice 
exhibit significantly higher Mdm2 expression levels compared to fibroblasts from 
Mdm2SNP309T/T mice after UVB treatment. Thus, these data indicate that the Mdm2 
expression levels differences are not insult dependent.  
A further examination of basal Mdm2 expression from different tissues harvested 
from SNP309 mice in a C57BL/6 background revealed considerable variation in Mdm2 
expression levels between tissues and within genotypes of SNP309 mice. Furthermore, 
there are some differences in Mdm2 expression between genders, suggesting that other 
factors cooperate with the SNP309 allele and alter Mdm2 expression in a tissue-
dependent manner through discrete mechanisms.  
The differences in Mdm2 expression between tissues were a surprise. Mdm2 
expression levels have not been thoroughly examined in all tissues, especially in normal 
samples. However, there is evidence from other ubiquitously expressed genes suggesting 
expression differences in different tissues. Previous studies, which have focused on 
characterizing and understanding the gene and protein spatial distributions in normal and 
diseased tissues, corroborate these finding: gene expression signatures vary among 
tissues [158, 159]. These results have been studied in healthy and diseased tissues of 
human and mice. Furthermore, the expression atlas (http://www.ebi.ac.uk/gxa/home) and 
protein atlas (http://www.proteinatlas.org) [160, 161] reveal gene and protein expression 
variation between tissues of human and mice. However, to my knowledge, no studies 
have demonstrated that a functional SNP contrastingly alters gene expression in tissues of 
the same organism. Thus, this is a novel observation. 
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The SNP309G allele cooperates with epidermal cell factors to regulate Mdm2 
expression in skin tissue  
 To understand the mechanism(s) that regulates SNP309-dependent Mdm2 
expression in epidermal skin tissue, I evaluated the transcription factors that regulate 
Mdm2 expression through the Mdm2 P2 promoter in keratinocytes from SNP309 mice. 
The ChIP-seq data from ENCODE confirmed that E2F6 binds to the MDM2-P2 promoter 
in cells expressing SNP309T/G alleles, harboring its binding signature adjacent to the 
SNP309 site, suggesting that E2F6 may have a role in SNP309-dependent Mdm2 
expression regulation. 
Our data show that Mdm2 expression in keratinocytes is controlled by the 
SNP309G allele through an E2F6 suppressive mechanism. Previous mechanistic studies 
both in human and mouse tissues show that SP1 preferentially binds to SNP309G allele to 
increase Mdm2 expression [107, 119]. Thus, I examined the role of SP1 on Mdm2 
expression regulation. Overexpression of SP1 in MEFs harvested from Mdm2SNP309T/T and 
Mdm2SNP309G/G mice show upregulation of Mdm2 expression in MEFs from 
Mdm2SNP309G/G mice, but there was no increase in Mdm2 expression in Mdm2SNP309T/T 
MEFs. In contrast, E2F6 overexpression experiments show preferential suppression of 
Mdm2 levels in MEFs harboring the SNP309G allele. Moreover, our ChIP assay 
confirmed that E2F6 preferentially binds to the Mdm2-P2 promoter in keratinocytes of 
SNP309G compared to SNP309T, suggesting that the SNP309G allele contrastingly alters 
Mdm2 expression depending on the transcription factor-Mdm2 P2 interactions. 
Furthermore, these contrasting differences in Mdm2 gene expression will dictate p53 
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function and stability. Thus, the SNP309G allele can exhibit tumor promoting, or tumor 
protective signatures in tissues depending on the SNP309G-dependent mechanism 
elicited to regulate Mdm2 expression.  
Our study shows that SNP309 directly alters basal Mdm2 expression in a cell-type 
dependent manner. Gene expression varies between tissues [162, 163]. Functional SNPs 
affect gene expression. However, most studies focus on how these variants alter gene 
function in the context of disease. This study is novel because we explore how functional 
SNPs alter gene function in normal tissues within the same organism; furthermore, we 
investigate discrete mechanisms that contrastingly regulate Mdm2 expression in an 
SNP309-dependent manner. To our knowledge, this is the first time a study reports how a 




To date, epidemiological studies do not associate MDM2 SNP309 with skin 
squamous cell carcinoma risk [164]; thus, it is possible that our results are particular to 
skin keratinocytes from mice. However, many meta-analyses associating MDM2 SNP309 
to cancer risk are conflicting, even in larger studies, suggesting that other factors can 
promote tumor risk. We also observed differences in expression when we stratified by 
gender, thus, supporting the hypothesis that other factors cooperate to alter gene 
expression in an SNP-dependent manner in different tissues. Our study expands our 
understanding of how SNP309 modulates Mdm2 function in healthy tissues. Thus, we 
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examined the tumor risk in skin tissues to validate the expression differences and define a 
discrete mechanism in SNP309 gene function. Furthermore, it is possible that the cohorts 
used in human studies harbor other SNPs within the MDM2 promoter that give a 
protective advantage to MDM2 SNP309, as in the case of MDM2 SNP285, a SNP that 


















Future directions  
Characterizing factors that affect SNP-dependent mechanism 
 
Functional polymorphisms are located within regulatory or protein coding 
sequences and alter gene regulation and influence disease risk [89-94]. Meta-analyses 
associate many SNPs with disease risk, but in most cases detailed molecular mechanisms 
have not been elucidated. Thus, the role of functional polymorphisms as clinical 
prognostic markers has not been fully appreciated.  
There is evidence suggesting that cooperating factors influence SNP-dependent 
gene regulation. Many meta-analyses associating SNPs and disease are stratified by 
factors, such as race, gender, and age; yet, these data are sometimes contradicting when 
comparing to other study cohorts. Thus, it is important to understand the influence of 
cooperating factors by studying their molecular mechanisms in robust, controlled, and 
otherwise isogenic experimental systems.  
In this study, we examined the role of environmental stress on Mdm2SNP309 mice. 
Our data show that environmental stress cooperates with the SNP309 to promote cancer 
risk. More importantly, our study suggests that Mdm2 SNP309 regulates Mdm2 
expression in a tissue-dependent manner. To our knowledge, this is the first study that 
shows contrasting differences in Mdm2 basal expression within the same organism, thus, 
highlighting the novelty of our findings. Furthermore, our data demonstrate that gender 
cooperates with SNP309-dependent Mdm2 regulation. This was evident when we 
examined other tissues besides skin and lymphatic tissues. Thus, further mechanistic 
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studies evaluating the regulatory influence of gender could yield important information 
that could be beneficial to clinical applications.   
 
Summary 
Meta-analysis studies associating functional polymorphisms and disease risk are 
important tools to evaluate study cohorts. However other factors, such as environmental 
stress, race, and gender may influence the effects of these SNPs within a study cohort. 
Furthermore, SNPs may influence tissue-specific gene regulation. Thus, further 
characterization of SNP-dependent regulation is needed to effectively evaluate the 
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